This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Celleoplasm: A PETHEMA Study
by
, , , , , , , , , , , , , , , , , , , , and add
Show full author list
Antonio Solana-Altabella
1,2,3
,
Irene Navarro-Vicente
2,4,
Eduardo Rodríguez-Arbolí
5,6,7,
Victor Noriega
8,
Josefina Serrano
9,
Teresa Bernal
10,
Vicente Carrasco-Baraja
11,
Raimundo Garcia-Boyero
12,
Carmen Olivier Cornacchia
13,
Lorenzo Algarra
14,
Eduardo López-Briz
1,3,
Armando Mena-Durán
15,
Jackeline Solano-Tovar
16,
Carmen Botella-Prieto
17,
Sara Sánchez-Sánchez
18,
Juan Miguel Bergua-Burgues
19,
Pilar Lloret-Madrid
2,4,
Mario Rodenas-Rovira
1,
Blanca Boluda
2,4,
Isabel Cano-Ferri
2,4,
Evelyn Acuña-Cruz
2,4,
Rebeca Rodríguez-Veiga
2,4,
Laura Torres-Miñana
2,4,
María Centelles-Oria
1,3,
José Luis Poveda-Andrés
1,3,
David Martínez-Cuadrón
2,4 and
Pau Montesinos
2,4,*add
Show full author list
1
Pharmacy Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
2
Accredited Research Group on Hematology, Instituto de Investigación Sanitaria La Fe (IISLAFE), 46026 Valencia, Spain
3
Accredited Research Group on Pharmacy, Instituto de Investigación Sanitaria La Fe (IISLAFE), 46026 Valencia, Spain
4
Hematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
5
Hematology Department, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain
6
Instituto de Biomedicina de Sevilla (IBIS/CSIC), 41009 Sevilla, Spain
7
Faculty of Medicine, Universidad de Sevilla, 41004 Sevilla, Spain
8
Hematology Department, Hospital Universitario A Coruña, 15006 A Coruña, Spain
9
Hematology Department, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), 14004 Córdoba, Spain
10
Hematology Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
11
Hematology Department, Hospital Universitario Royo Villanova, 50015 Zaragoza, Spain
12
Hematology Department, Hospital General Universitari de Castelló, 12004 Castellón de la Plana, Spain
13
Hematology Department, Complejo Asistencial de Segovia, 40002 Segovia, Spain
14
Hematology Department, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain
15
Hematology Department, Hospital General Universitario de Valencia, 46014 Valencia, Spain
16
Hematology Department, Complejo Asistencial de Palencia, 34005 Palencia, Spain
17
Hematology Department, Hospital General Universitario Dr. Balmis, 03010 Alicante, Spain
18
Hematology Department, Hospital Marina Baixa, 03570 Villajoyosa, Spain
19
Hematology Department, Hospital San Pedro de Alcántara, 10003 Cáceres, Spain
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(17), 2844; https://doi.org/10.3390/cancers17172844
Submission received: 9 July 2025
/
Revised: 17 August 2025
/
Accepted: 27 August 2025
/
Published: 29 August 2025
(This article belongs to the Collection Acute Myeloid Leukemia (AML))
Simple Summary
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and aggressive blood cancer that often requires intensive medical care. In this study, we looked at how much it actually costs to treat patients with this disease and how often they use hospital services. The average cost per patient is over EUR 100,000, and hospital stays make up a big part of that. These patients spend a lot of time in hospital, which shows just how demanding this condition is on the healthcare system. These data are especially important when dealing with rare diseases, where resources are limited and treatment choices can be complex.
Abstract
Background/Objectives: Information on the economic impact and healthcare resource utilization (HCRU) associated with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is lacking. Methods: A retrospective review of medical records identified patients diagnosed with BPDCN between 2009 and 2023. Data on outpatient resource use, reimbursement, frequency and duration of hospitalizations, and transfusion burden were collected from diagnosis to death or last follow-up. Results: A total of 38 patients with a median age of 66 years were included. Conventional intensive chemotherapy (CHT) regimens were initially administered to 58% of patients, while targeted therapies were used in 37% of cases. The ratio of total days hospitalized to the overall follow-up period was 17%, with a total of 182 hospitalizations (average of 5 per patient; mean duration 20 days). The mean total reimbursement was EUR 109,104 per patient, primarily attributed to hospital admissions (EUR 89,158; EUR 18,118 per hospitalization). Hospitalizations before or without any allogeneic hematopoietic stem cell transplant (alloHSCT) accounted for 70% of total admissions, with an average overall cost of EUR 50,285 per patient (EUR 12,427 per hospitalization). AlloHSCT-period hospitalizations occurred in 18 patients, with a mean total reimbursement of EUR 122,497 per patient and EUR 30,464 per hospitalization. Conclusions: The active treatment of BPDCN imposes a high economic burden and extensive HCRU. Comparative pharmacoeconomic studies evaluating the cost-effectiveness of new therapies for BPDCN are needed to identify patient subgroups that may benefit most from these treatments.
